ArticleCentral-European journal of immunology2025
Immune disorders and COVID-19 vaccination: analysing anti-SARS-CoV-2 antibody levels and cellular immune response.
Article in Central-European journal of immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Immune disorders, especially in individuals with humoral deficiencies, pose challenges during the COVID-19 pandemic. Vaccination efficacy in this population remains a critical concern amid circulating misinformation. This study aimed to analyse the post-COVID-19 vaccination immune response in individuals with immune disorders, focusing on humoral deficiency. The goal was to provide essential insights for tailored vaccination strategies. Material and methods: Tests including Anti-SARS-CoV-2 QuantiVac ELISA, SARS-CoV-2 NeutraLISA, and Quan-T-Cell SARS-CoV-2 IGRA were conducted on 63 patients with humoral inborn errors of immunity. Statistical analysis employed descriptive statistics and visualizations. Results: Patients exhibited diverse responses based on immunological diagnoses. Immunoglobulin G (IgG) antibody levels varied across disorders, with agammaglobulinaemia patients showing lower levels but positive interferon responses. IgG subclass deficiency patients demonstrated robust antibody and neutralizing responses. Other antibody production disorders displayed strong immune reactions. Common variable immunodeficiency patients, particularly adults, exhibited higher antibody levels, increased neutralization, and pronounced interferon responses compared to children. Conclusions: This study underscores the nuanced immune responses in individuals with diverse immune disorders following COVID-19 vaccination. Insights into specific disorder-related variations provide a foundation for targeted vaccination approaches, contributing to enhanced protection in this vulnerable population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.